Cadrenal Therapeutics, Inc. announced on March 4, 2025, the signing of a Collaboration Agreement with Abbott (NYSE: ABT). This agreement is set to support Cadrenal’s pivotal TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial.
Under the terms of the agreement, Abbott will provide valuable insights derived from its recent HeartMate 3™ clinical trials. Abbott will also offer support to Cadrenal in areas such as trial design, site identification, trial awareness, and HeartMate 3™ expertise.
This collaboration validates the critical market need for a new anticoagulant specifically for patients with left ventricular assist devices (LVADs). The partnership is expected to significantly advance the development of tecarfarin for this underserved patient population.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.